DTS-101(DTS-101) - 药物靶点：DNA x Top II_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

DNA x Top II

作用机制

DNA嵌入剂、Top II抑制剂(拓扑异构酶II抑制剂)

治疗领域

肿瘤

在研适应症-

非在研适应症

肿瘤

原研机构

Facultés Universitaires Catholiques de Mons

在研机构-

非在研机构

Facultés Universitaires Catholiques de Mons

Diatos SA

最高研发阶段终止临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 DTS-101 相关的临床结果

登录后查看更多信息

100 项与 DTS-101 相关的转化医学

登录后查看更多信息

100 项与 DTS-101 相关的专利（医药）

登录后查看更多信息

1

项与 DTS-101 相关的文献（医药）

2020-05-01·Heliyon

Cytotoxic effect of selected wild orchids on two different human cancer cell lines

Article

作者: Pradhan, Shreeti ; Joshi, Pusp Raj ; Chand, Mukesh Babu ; Bohara, Manoj ; Wagner, Sven H ; Pant, Krishna Kumar ; Pant, Bijaya ; Pant, Basant ; Paudel, Mukti Ram ; Joshi, Giri Prasad

Majority of the orchid species are used in the traditional medicines for the treatment of several diseases. They are the sources of polysaccharides, phenanthrenes, bibenzyl derivatives, revesteral, stilbenoids and polyphenol compounds. This study explored the cytotoxic activity of seven wild orchid species and identification of medicinally active compounds. The extracts of orchid species were screened for cytotoxic effect on the human cervical cancer cells (HeLa) and human glioblastoma cells (U251) using an MTT assay. The medicinally active compounds of high cytotoxic extracts were identified by GC-MS resulting in many stilbenoids and phenolic derivatives. The extract of Dendrobium transparens (DTs) and Vanda cristata (VCw) showed high cytotoxic effect towards the HeLa and U251 cell lines (IC₅₀ of DTs: 382.14 μg/ml and 75.84 μg/ml respectively and IC₅₀ of VCw: 317.23 μg/ml and 163.66 μg/ml respectively). This study concludes that they could be used as cancer therapeutics.

100 项与 DTS-101 相关的药物交易

登录后查看更多信息